MASH patients with clinically significant liver fibrosis (stages F2 and F3) are at high risk for progression to cirrhosis, which places them at greater risk for hepatocellular carcinoma ...
To find out, Lu's group first induced liver inflammation and fibrosis in lab mice. They then treated those mice with a substance known as FDI-6 that blocks the protein produced by the FOXM1 gene.
Hepatic fibrosis is the common result of injury to the liver from a variety of damaging mechanisms, and the accurate assessment of the degree of fibrosis is clinically important. For many years ...
The multicenter, randomized, double-blind ESSENCE trial (ClinicalTrial.gov Identifier: NCT04822181) included 1200 patients with MASH with moderate to advanced liver fibrosis (stage 2 or 3).